N/A N=80 Impact of Volunteer Peer-Led Intervention for Weight Control in Primary Care
Weight Loss
Primary: Percent Change in Weight — -1.27; -2.76 percent weight change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=61 Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder
Autism Spectrum Disorder
Primary: Treatment Responder — 9; 4 Participants
Phase 4 N=8 A Study to Determine if Caffeine Accelerates Emergence From Propofol Anesthesia
Anesthesia
Primary: Waking Time - Time Between Terminating Anesthesia and Subject Opening Eyes.
Phase 4 N=8 A Study to Determine if Caffeine Accelerates Emergence From Anesthesia
Anesthesia
Primary: Waking Time - Re-establishment of the Gag Reflex. — 16.45; 9.57 minutes — p=0.002
Phase 4 N=44 Eovist vs. Dotarem Healthy Volunteer MRI
Transient Severe Arterial Phase Motion
Primary: Subject Breath Hold Capacity, as Measured by Number of Seconds a Subject Can Hold His/Her Breath — 28; 38; 35 seconds
Phase 2 N=10 A Healthy Volunteer Trial Investigating MR-enterography Image Quality of Lumentin® 44
Healthy
Primary: Visual Evaluation of MRE Images - Motility — 0; 6; 4; 0 Participants
N/A N=20 EPO2-PV: Evaluation of Pre-Oxygenation Conditions in Morbidly Obese Volunteer: Effect of Position and Ventilation Mode
Morbid Obesity · Bariatric Surgery Candidate
Primary: Functional Residual Capacity — 2573; 2145; 2456; 2219 ml
N/A N=173 MEMORI Corps: Activity-based Companion Care for Dementia
Alzheimer Disease · Dementia
Primary: Change in Neuropsychiatric Symptoms as Assessed by Neuropsychiatric Inventory (NPI) Score — 3.35; 0.47 score on a scale
Phase 1 N=14 A Study to Assess the Pharmacokinetics and Safety of Different Forms and Formulations of AZD9496 in Healthy Subjects
Breast Cancer
Primary: Pharmacokinetics: Maximum Plasma Concentration (Cmax) for AZD9496 and Its Metabolites at Each Treatment Period. — 64.85; 381.0; 138.2; 91.83 ng/mL
Phase 3 N=200 Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults
Anthrax
Primary: Percentage of Subjects Achieving a TNA Response of a Predefined Threshold Value at Day 63 (5 Weeks Following the Third Vaccination on Day 28). — 71.2; 68.5; 73.9; 76.7…
Phase 2 N=107 A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects
Bleeding
Primary: Percent Change in Anti-Fxa Activity From Baseline to the End of Infusion (EOI) Nadir. — -94.50; -29.00; -98.00; -37.00 percent change — p=0.0275
Phase 1 N=88 Phase I, KM-819 in Healthy Subjects for Parkinson's Disease
Parkinson's Disease
Primary: Number of Participants With Adverse Events — 2; 2; 2; 1 participants
Phase 1 N=67 Bioequivalence Study of Tacrolimus in Healthy Volunteers
Healthy Volunteers
Primary: Area Under the Concentration (AUC 72) — 37434.51; 33716.80 pg.h/mL
Phase 1 N=74 Pharmacokinetics and Pharmacodynamics Study of BCD-066 Compared to Aranesp® in Healthy Volunteers
Healthy
Primary: AUC — 150607; 152208; 504584; 544818 (pg/ml)*hour
Phase 1 N=6 Clinical Trial to Study 4 Different Doses of the Vaccine RUTI in Healthy Volunteers
Latent Tuberculosis Infection · Tuberculosis
Primary: VAS Pain Score (Visual Analogic Scale, That Ranges From 0 to 100) to Evaluate Each Volunteer Subjective Pain Intensity at the Inoculation Point